Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients

COVID-19 caused by SARS-CoV-2, is an international concern. This infection requires urgent efforts to develop new antiviral compounds. To date, no specific drug in controlling this disease has been identified. Developing the new treatment is usually time consuming, therefore using the repurposing br...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghanbari, Reza, Teimoori, Ali, Sadeghi, Anahita, Mohamadkhani, Ashraf, Rezasoltani, Sama, Asadi, Ebrahim, Jouyban, Abolghasem, Sumner, Susan CJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789744/
https://www.ncbi.nlm.nih.gov/pubmed/33404263
http://dx.doi.org/10.2217/fmb-2020-0120
Descripción
Sumario:COVID-19 caused by SARS-CoV-2, is an international concern. This infection requires urgent efforts to develop new antiviral compounds. To date, no specific drug in controlling this disease has been identified. Developing the new treatment is usually time consuming, therefore using the repurposing broad-spectrum antiviral drugs could be an effective strategy to respond immediately. In this review, a number of broad-spectrum antivirals with potential efficacy to inhibit the virus replication via targeting the virus spike protein (S protein), RNA-dependent RNA polymerase (RdRp), 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro) that are critical in the pathogenesis and life cycle of coronavirus, have been evaluated as possible treatment options against SARS-CoV-2 in COVID-19 patients.

Ejemplares similares